Gastroesophageal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastric Cancer (662)

Gastroesophageal Junction Adenocarcinoma (160)

Gastric Adenocarcinoma (35)

Gastric Cancer (662)

Gastroesophageal Junction Adenocarcinoma (160)

Gastric Adenocarcinoma (35)

›

HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ZW25 Sensitive : C3 ASCO-GI 2023 - 2wk	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ZW25 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
HER-2 amplification	Gastroesophageal Cancer	HER-2 amplification	Gastroesophageal Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab + trastuzumab Sensitive: C1 - Off-label pembrolizumab + trastuzumab Sensitive : C1	pembrolizumab + trastuzumab Sensitive: C1 - Off-label pembrolizumab + trastuzumab Sensitive : C1
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
TP53 mutation	Gastroesophageal Cancer	TP53 mutation	Gastroesophageal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TET1 mutation	Gastroesophageal Cancer	TET1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
TGFB1 elevation	Gastroesophageal Cancer	TGFB1 elevation	Gastroesophageal Cancer	M7824 Sensitive: C3 – Early Trials M7824 Sensitive : C3	M7824 Sensitive: C3 – Early Trials M7824 Sensitive : C3
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ZW25 Sensitive : C3	ZW25 Sensitive: C3 – Early Trials ZW25 Sensitive : C3
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3
EGFR amplification + ERBB2 amplification	Gastroesophageal Cancer	EGFR amplification + ERBB2 amplification	Gastroesophageal Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
CFB overexpression	Gastroesophageal Cancer	CFB overexpression	Gastroesophageal Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
VEGFC-H	Gastroesophageal Cancer	VEGFC-H	Gastroesophageal Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
POLE mutation	Gastroesophageal Cancer	POLE mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
POLD1 mutation	Gastroesophageal Cancer	POLD1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
HER-2 positive + HER-2 amplification	Gastroesophageal Cancer	HER-2 positive + HER-2 amplification	Gastroesophageal Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
CTAG1A expression	Gastroesophageal Cancer	CTAG1A expression	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	margetuximab + retifanlimab Sensitive: C3 – Early Trials margetuximab + retifanlimab Sensitive : C3	margetuximab + retifanlimab Sensitive: C3 – Early Trials margetuximab + retifanlimab Sensitive : C3
HER-2 mutation	Gastroesophageal Cancer	HER-2 mutation	Gastroesophageal Cancer	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D
HER-2 mutation	Gastroesophageal Cancer	HER-2 mutation	Gastroesophageal Cancer	neratinib Sensitive: D – Preclinical neratinib Sensitive : D	neratinib Sensitive: D – Preclinical neratinib Sensitive : D
HER-2 mutation	Gastroesophageal Cancer	HER-2 mutation	Gastroesophageal Cancer	dasatinib + neratinib Sensitive: D – Preclinical dasatinib + neratinib Sensitive : D	dasatinib + neratinib Sensitive: D – Preclinical dasatinib + neratinib Sensitive : D
BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer	BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer	AT 101 Sensitive: D – Preclinical AT 101 Sensitive : D	AT 101 Sensitive: D – Preclinical AT 101 Sensitive : D

Gastroesophageal Cancer

Associations(38)

Associations
(38)